Stoke Therapeutics (STOK) Accounts Payables (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Accounts Payables of $6.8 million for Q1 2026, up 212.85% year-over-year from $2.2 million in Q1 2025, and up 38.47% quarter-over-quarter from $4.9 million in Q4 2025.
Stoke Therapeutics (STOK) Accounts Payables (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 212.85% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (up 212.85% YoY), while the FY2025 annual figure was $4.9 million, up 97.72% from the prior year.
- Accounts Payables for Q1 2026 stood at $6.8 million, up from $4.9 million in the prior quarter.
- The five-year high for Accounts Payables was $6.8 million in Q1 2026, with the low at $766000.0 in Q4 2022.
- The 5-year median for Accounts Payables is $3.1 million (2023), against an average of $3.3 million.
- Peak annual rise in Accounts Payables reached 274.04% in 2022, while the deepest fall reached 67.88% in 2022.
- Stoke Therapeutics' Accounts Payables stood at $766000.0 in 2022, then surged by 121.28% to $1.7 million in 2023, then surged by 47.37% to $2.5 million in 2024, then soared by 97.72% to $4.9 million in 2025, then surged by 38.47% to $6.8 million in 2026.
- Business Quant data shows STOK's Accounts Payables at $6.8 million in Q1 2026, $4.9 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 4.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.79 Mn |
| Mar 31, 2026 | 6.84 Mn |
| Dec 31, 2025 | 4.94 Mn |
| Sep 30, 2025 | 5.87 Mn |
| Jun 30, 2025 | 4.31 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Sep 30, 2024 | 2.49 Mn |
| Jun 30, 2024 | 3.95 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 3.08 Mn |
| Jun 30, 2023 | 1.56 Mn |
| Mar 31, 2023 | 4.30 Mn |
| Dec 31, 2022 | 766,000.00 |
| Sep 30, 2022 | 1.91 Mn |
| Jun 30, 2022 | 3.60 Mn |
| Mar 31, 2022 | 3.33 Mn |
| Dec 31, 2021 | 2.39 Mn |
| Sep 30, 2021 | 655,000.00 |